20 June 2018

ASX ANNOUNCEMENT

SOZO® Abstract Presentation at 23rd World Congress on Heart Disease

Brisbane, Australia - ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announced the acceptance of an abstract for presentation at the 23rd World Congress on Heart Disease.

The Congress is sponsored by the International Academy of Cardiology and will be held at the Westin Copley Place in Boston, MA, USA, July 27-29, 2018. This major Congress provides a comprehensive overview of the latest research developments in cardiovascular medicine, primarily in the areas of molecular biology, coronary artery disease, heart failure, cardiac arrhythmias and cardiac surgery. Last year clinicians from thirty-two countries participated in the meeting.

The abstract titled Utilization of bioimpedance spectroscopy in lieu of invasive monitoring for monitoring fluid overload has been accepted for presentation in the Poster Session “Heart Failure: Diagnosis and Management” for the Advanced Scientific Program for Friday July 27, 2018. This abstract will be published in the online journal of CARDIOLOGY following the meeting.

Information on the Congress can be found at the following link:


Richard Carreon
Managing Director & CEO

Media Contact:
Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.